Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.41 USD | +0.71% | +0.71% | +33.02% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 8M | Capitalization | 81.43M |
---|---|---|---|---|---|
Net income 2024 * | -38M | Net income 2025 * | -37M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 10.2 x |
P/E ratio 2024 * |
-2.01
x | P/E ratio 2025 * |
-2.03
x | Employees | 16 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.73% |
Latest transcript on SELLAS Life Sciences Group, Inc.
1 day | +0.71% | ||
1 week | +0.71% | ||
1 month | +13.71% | ||
3 months | +39.60% | ||
6 months | +35.58% | ||
Current year | +33.02% |
Managers | Title | Age | Since |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 06-04-02 |
John Burns
DFI | Director of Finance/CFO | 39 | 13-04-30 |
Andrew Elnatan
LAW | General Counsel | - | 23-01-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 17-12-28 | |
David Scheinberg
BRD | Director/Board Member | 68 | 17-11-30 |
John Varian
BRD | Director/Board Member | 64 | 17-12-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 1.41 | +0.71% | 571,466 |
24-05-30 | 1.4 | +3.70% | 477,270 |
24-05-29 | 1.35 | -2.17% | 459,162 |
24-05-28 | 1.38 | -1.43% | 532,057 |
24-05-24 | 1.4 | +3.70% | 438,889 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.02% | 81.43M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SLS Stock